Ulcerative Colitis Treatment in Dallas, TX

What Is Ulcerative Colitis?

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that causes persistent inflammation and ulceration of the innermost lining (mucosa) of the colon (large intestine) and rectum. Unlike Crohn's disease, which can affect any segment of the gastrointestinal tract in a patchy or "skip" pattern, ulcerative colitis involves only the colon and rectum and produces a continuous pattern of inflammation that begins at the rectum and extends proximally without interruption. Approximately 900,000 Americans are currently living with ulcerative colitis, according to data from the Crohn's & Colitis Foundation, making it one of the two major forms of IBD alongside Crohn's disease.

In ulcerative colitis, the immune system mounts an abnormal inflammatory response against the lining of the colon. This results in chronic mucosal inflammation, the formation of small open sores (ulcers), and disruption of the colon's ability to absorb water and form solid stool. The disease follows a relapsing-remitting course, meaning patients experience periods of active symptoms (flares) alternating with periods of relative or complete symptom relief (remission). The severity and frequency of flares vary widely among individuals and can change over the course of a patient's lifetime.

At Texas Gut Health in Sachse, TX, Dr. Jaison John provides expert diagnosis and long-term management of ulcerative colitis for patients throughout the Dallas-Fort Worth metroplex. Dr. John completed his gastroenterology fellowship at UT Medical Branch, where he served as Chief Fellow, and his internal medicine residency at UT Austin Dell Medical School, where he served as Chief Resident. He holds dual board certifications from the American Board of Internal Medicine (ABIM) in both internal medicine and gastroenterology, and he follows the latest evidence-based guidelines from the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) in managing inflammatory bowel disease.

Ulcerative Colitis vs. Crohn's Disease

Ulcerative colitis and Crohn's disease are the two primary forms of inflammatory bowel disease, and while they share some overlapping symptoms, they are distinct conditions with important clinical differences. Accurately distinguishing between the two is essential for selecting the most effective treatment approach. The key differences include:

• Location of inflammation: Ulcerative colitis affects only the colon and rectum. Crohn's disease can involve any part of the gastrointestinal tract, from the mouth to the anus, though it most commonly affects the terminal ileum (the end of the small intestine) and the colon.
• Pattern of inflammation: UC causes continuous, uninterrupted inflammation that starts at the rectum and extends upward through part or all of the colon. Crohn's disease often causes "skip lesions," with areas of inflamed tissue interspersed with healthy segments.
• Depth of inflammation: Ulcerative colitis involves only the mucosal layer — the innermost lining of the colon wall. Crohn's disease can cause transmural inflammation, meaning it can penetrate through the full thickness of the bowel wall, which can lead to complications such as strictures (narrowing), fistulas (abnormal connections between organs), and abscesses.
• Complications: UC primarily causes bleeding, diarrhea, and, in long-standing disease, an increased risk of colorectal cancer. Crohn's disease is more likely to cause strictures, fistulas, perianal disease, and nutritional deficiencies due to small bowel involvement.
• Surgical outcome: Surgical removal of the colon and rectum (proctocolectomy) is considered curative for ulcerative colitis because the disease is confined to these organs. Surgery for Crohn's disease is not curative, as the disease can recur in other parts of the GI tract after resection.

In approximately 5% to 15% of IBD cases, the initial presentation may not clearly fit either diagnosis, a situation termed "indeterminate colitis." Dr. John uses a combination of colonoscopy with biopsy, upper endoscopy, imaging studies, serologic markers, and clinical assessment to establish the most accurate diagnosis and guide treatment decisions.

Types of Ulcerative Colitis

Ulcerative colitis is classified by the extent of colonic involvement, which directly influences treatment selection, prognosis, and cancer surveillance recommendations. The four main types are:

• Ulcerative proctitis: Inflammation is limited to the rectum (the last 15 to 20 centimeters of the colon). This is the mildest form of UC and accounts for approximately 25% to 30% of new diagnoses. Symptoms typically include rectal bleeding, urgency, and tenesmus (a sensation of incomplete evacuation). Patients with ulcerative proctitis often respond well to topical therapies such as mesalamine suppositories or enemas.
• Proctosigmoiditis: Inflammation extends from the rectum into the sigmoid colon, the S-shaped segment immediately above the rectum. Symptoms include bloody diarrhea, abdominal cramping concentrated in the lower left abdomen, urgency, and tenesmus. Treatment typically combines oral and topical aminosalicylates.
• Left-sided colitis (distal colitis): Inflammation extends continuously from the rectum to the splenic flexure, the point where the colon turns from the transverse to the descending segment. Left-sided colitis accounts for a significant proportion of UC cases and often causes more pronounced bloody diarrhea, abdominal pain on the left side, and weight loss. Treatment may require a combination of oral aminosalicylates, topical therapy, and, for moderate-to-severe disease, immunomodulators or biologic agents.
• Pancolitis (extensive colitis): Inflammation involves the entire colon from the rectum to the cecum. Pancolitis represents the most extensive form of UC and is associated with the most significant symptoms, including profuse bloody diarrhea, severe abdominal pain, fatigue, fever, and weight loss. Patients with pancolitis have the highest risk of complications, including toxic megacolon and colorectal cancer, and typically require systemic therapies such as biologics, immunomodulators, or small-molecule drugs to achieve and maintain remission.

It is important to understand that ulcerative colitis can progress in extent over time. A patient initially diagnosed with proctitis may later develop left-sided colitis or pancolitis. Regular colonoscopic evaluation allows Dr. John to monitor disease extent and adjust treatment accordingly.

Symptoms of Ulcerative Colitis

The symptoms of ulcerative colitis vary in severity depending on the extent and intensity of inflammation in the colon. Symptoms may develop gradually over weeks to months or, in some cases, begin more acutely. The most common symptoms include:

• Bloody diarrhea: The hallmark symptom of ulcerative colitis. Patients frequently notice blood mixed with stool or visible on the surface of the stool. The blood may be bright red, dark red, or accompanied by mucus. During active flares, patients may have 6 to 20 or more bowel movements per day.
• Rectal urgency: An intense, sudden need to have a bowel movement that can be difficult to control. Urgency is one of the most disruptive symptoms of UC and can significantly affect quality of life, work, and social activities.
• Tenesmus: A persistent feeling of needing to pass stool even when the rectum is empty. This cramping, uncomfortable sensation is caused by inflammation of the rectal lining and is particularly common in patients with proctitis or proctosigmoiditis.
• Abdominal pain and cramping: Crampy abdominal pain, typically in the lower left quadrant, often occurs before or during bowel movements. In severe or extensive disease, pain may be more diffuse across the abdomen.
• Fatigue: Chronic fatigue is one of the most prevalent and underappreciated symptoms of UC. It can result from ongoing inflammation, anemia due to chronic blood loss, disrupted sleep from nighttime bowel movements, and the overall burden of chronic disease.
• Unintentional weight loss: Patients with moderate-to-severe UC may lose weight due to reduced appetite, malabsorption, and increased metabolic demands from chronic inflammation.
• Fever: Low-grade fever may accompany active flares and can be a sign of moderate-to-severe disease activity.
• Extraintestinal manifestations: Approximately 25% to 40% of UC patients experience symptoms outside the gastrointestinal tract, including joint pain or swelling (arthritis), skin conditions such as erythema nodosum or pyoderma gangrenosum, eye inflammation (uveitis or episcleritis), and liver conditions such as primary sclerosing cholangitis (PSC).

Causes and Risk Factors

The exact cause of ulcerative colitis is not fully understood, but current scientific evidence, as summarized in guidelines from the ACG and AGA, indicates that UC results from a complex interaction between genetic predisposition, immune system dysregulation, environmental factors, and alterations in the gut microbiome. Ulcerative colitis is not caused by stress, diet, or any specific food, although these factors can influence symptom severity and flare frequency in people who already have the disease.

Immune System Dysregulation

Ulcerative colitis is fundamentally an immune-mediated condition. In healthy individuals, the immune system in the gut maintains a careful balance between defending against harmful pathogens and tolerating the trillions of beneficial bacteria that inhabit the colon. In UC, this balance breaks down. The immune system launches an inappropriate, sustained inflammatory attack against the normal colonic tissue, particularly the mucosal lining. This chronic inflammation leads to the tissue damage, ulceration, and symptoms characteristic of the disease. Researchers believe that this immune dysregulation may be triggered by an initial event — such as a gastrointestinal infection — in a genetically susceptible individual, but the precise triggering mechanism remains an active area of research.

Genetic Factors

Genetics play a significant role in UC susceptibility. More than 200 genetic loci have been associated with inflammatory bowel disease, many of which are involved in immune regulation, barrier function of the intestinal lining, and microbial recognition. Having a first-degree relative (parent, sibling, or child) with ulcerative colitis increases your risk of developing the disease by 4- to 15-fold compared to the general population. Individuals of Ashkenazi Jewish descent have a higher prevalence of UC than other ethnic groups, further supporting a genetic component.

Environmental Factors

Several environmental factors have been linked to the development or modification of ulcerative colitis risk:

• Geographic distribution: UC is more common in developed, industrialized nations and in urban environments, suggesting that factors related to modernization, sanitation, and diet may contribute to disease risk.
• The non-smoking paradox: One of the most consistent and counterintuitive findings in IBD research is that current smoking appears to have a protective effect against ulcerative colitis. Former smokers have a higher risk of developing UC than people who have never smoked, and some patients develop UC shortly after quitting smoking. This is in stark contrast to Crohn's disease, where smoking worsens the condition. Despite this association, smoking is never recommended as a treatment due to its well-established and serious health risks.
• Prior appendectomy: Surgical removal of the appendix, particularly when performed for appendicitis before age 20, has been associated with a reduced risk of developing ulcerative colitis in multiple epidemiologic studies.
• NSAID use: Nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen can exacerbate UC symptoms and may trigger flares in some patients.
• Gut microbiome changes: Patients with UC have been shown to have altered compositions of gut bacteria (dysbiosis) compared to healthy individuals, though it remains unclear whether these changes are a cause or consequence of the disease.

Age and Demographics

Ulcerative colitis can develop at any age, but the peak age of onset occurs between 15 and 30 years, with a smaller secondary peak between ages 50 and 70. The disease affects men and women at roughly equal rates. UC is most prevalent in North America and Northern Europe, though its incidence is rising in previously low-prevalence regions such as Asia, South America, and the Middle East, a trend believed to reflect increasing industrialization and westernization of diet and lifestyle.

How Is Ulcerative Colitis Diagnosed?

Diagnosing ulcerative colitis requires a systematic approach that combines clinical evaluation, laboratory testing, endoscopic examination, and histologic (tissue) analysis. No single test can confirm the diagnosis on its own. At Texas Gut Health, Dr. John follows the diagnostic framework recommended by the ACG and AGA to ensure an accurate and timely diagnosis.

Colonoscopy with Biopsy

Colonoscopy is the gold standard for diagnosing ulcerative colitis. During the procedure, Dr. John uses a flexible, lighted scope to directly examine the entire colon and rectum, assessing the pattern, extent, and severity of mucosal inflammation. In UC, the colonoscopy typically reveals continuous erythema (redness), edema (swelling), loss of the normal vascular pattern, granularity, friability (tissue that bleeds easily when touched), and ulceration beginning at the rectum and extending proximally without skip areas. Multiple tissue biopsies are taken throughout the colon and sent for histologic analysis, which can confirm chronic architectural changes characteristic of UC, such as crypt distortion, crypt branching, and basal plasmacytosis.

Blood Tests

Blood tests provide valuable supporting information in the diagnostic workup. Common findings in active UC include:

• Elevated inflammatory markers: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are often elevated during active disease, reflecting systemic inflammation.
• Anemia: Iron-deficiency anemia is common due to chronic blood loss from the inflamed colon.
• Low albumin: Hypoalbuminemia may indicate more severe or extensive disease.
• Serologic markers: Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) are found in approximately 60% to 70% of UC patients and can help differentiate UC from Crohn's disease in ambiguous cases.

Stool Tests

Stool testing plays an important role in both initial diagnosis and ongoing disease monitoring:

• Fecal calprotectin: This stool biomarker is highly sensitive for intestinal inflammation and is particularly useful for distinguishing IBD from functional conditions such as irritable bowel syndrome (IBS). Elevated fecal calprotectin levels strongly suggest active mucosal inflammation and can also be used to monitor treatment response and detect early flares.
• Stool cultures and pathogen testing: Infectious causes of colitis (such as Clostridioides difficile, Salmonella, Shigella, and Campylobacter) must be excluded before a diagnosis of UC can be established, as these infections can mimic or complicate IBD.

Imaging Studies

While colonoscopy is the primary diagnostic tool, imaging studies may be used in certain situations to supplement the evaluation. CT scan or MR enterography can help assess for complications, rule out Crohn's disease involving the small bowel, and evaluate patients who present with severe symptoms where full colonoscopy may not be safe. Abdominal X-rays can be used to screen for toxic megacolon in acutely ill patients.

Treatment Options for Ulcerative Colitis

The goals of ulcerative colitis treatment are to induce remission during active flares, maintain long-term remission, prevent complications, improve quality of life, and achieve mucosal healing (the absence of visible inflammation on colonoscopy). Treatment is guided by disease severity (mild, moderate, or severe), disease extent (proctitis, left-sided, or extensive), and the patient's individual response to prior therapies. Dr. John develops a personalized treatment plan for each patient based on current ACG and AGA guidelines.

Aminosalicylates (5-ASA)

Aminosalicylates, also known as 5-ASA drugs, are the first-line therapy for mild-to-moderate ulcerative colitis and the most commonly prescribed medication class for UC. These medications work by reducing inflammation directly at the mucosal surface of the colon. The most widely used aminosalicylate is mesalamine, which is available in oral formulations (tablets and granules), rectal suppositories, and enemas. For patients with proctitis or left-sided disease, combining oral and topical (rectal) mesalamine is significantly more effective than either route alone, a strategy endorsed by the ACG. Other aminosalicylates include sulfasalazine, balsalazide, and olsalazine.

Corticosteroids

Corticosteroids such as prednisone, prednisolone, methylprednisolone, and budesonide are used to rapidly reduce inflammation during moderate-to-severe UC flares. They are highly effective for short-term symptom control but are not appropriate for long-term maintenance therapy due to significant side effects with prolonged use, including bone loss, weight gain, elevated blood sugar, increased infection risk, and adrenal suppression. The treatment goal is always to taper off corticosteroids once remission is achieved and transition to a steroid-sparing maintenance therapy.

Immunomodulators

Immunomodulator medications, including azathioprine, 6-mercaptopurine, and methotrexate, work by broadly suppressing the immune system to reduce colonic inflammation. These drugs are used as steroid-sparing maintenance therapies for patients with moderate UC who have difficulty tapering off corticosteroids, or as adjunctive therapy alongside biologic agents to reduce the formation of anti-drug antibodies and improve biologic efficacy. Immunomodulators typically take 8 to 12 weeks to reach full effect and require regular blood monitoring for potential side effects including bone marrow suppression and liver toxicity.

Biologic Therapies

Biologic therapies represent a major advance in the treatment of moderate-to-severe ulcerative colitis. These medications are engineered proteins derived from living cells that target specific components of the immune system responsible for driving chronic inflammation. The biologic classes approved for UC include:

• Anti-TNF agents: Infliximab (Remicade), adalimumab (Humira), and golimumab (Simponi) block tumor necrosis factor-alpha (TNF-alpha), a key pro-inflammatory cytokine. Anti-TNF agents were the first biologic class approved for UC and have extensive long-term safety and efficacy data. Infliximab is administered through intravenous infusion, while adalimumab and golimumab are given as subcutaneous injections.
• Anti-integrin therapy: Vedolizumab (Entyvio) blocks the alpha-4-beta-7 integrin, preventing inflammatory white blood cells from migrating into the gut tissue. Because vedolizumab acts selectively on the gut, it has a favorable safety profile with a lower risk of systemic immunosuppression compared to anti-TNF agents. It is administered through intravenous infusion.
• Anti-interleukin therapy: Ustekinumab (Stelara) blocks interleukin-12 and interleukin-23, two cytokines involved in the inflammatory cascade in IBD. Ustekinumab is given as an initial intravenous loading dose followed by subcutaneous injections for maintenance.

Texas Gut Health offers on-site infusion therapy services for patients receiving intravenous biologic medications, providing a comfortable and convenient treatment environment close to home for patients in Sachse, Murphy, Wylie, Plano, Garland, and the broader Dallas-Fort Worth area.

Small-Molecule Therapies

Small-molecule drugs are oral medications that have transformed the treatment landscape for moderate-to-severe ulcerative colitis in recent years. Unlike biologics, which are large proteins administered by injection or infusion, small-molecule drugs are taken by mouth, which many patients find more convenient. The two main classes include:

• Janus kinase (JAK) inhibitors: Tofacitinib (Xeljanz) and upadacitinib (Rinvoq) block Janus kinase enzymes, which are involved in intracellular signaling pathways that drive inflammation. JAK inhibitors have a rapid onset of action — many patients notice improvement within days to weeks — and are effective in patients who have not responded to biologic therapies. These medications require monitoring for potential side effects including elevated cholesterol, herpes zoster (shingles) reactivation, and venous thromboembolism.
• Sphingosine-1-phosphate (S1P) receptor modulators: Ozanimod (Zeposia) works by trapping certain lymphocytes in the lymph nodes, preventing them from traveling to the colon and contributing to inflammation. S1P modulators offer a novel mechanism of action and represent an additional oral treatment option for patients with moderate-to-severe UC.

Surgery for Ulcerative Colitis

Approximately 15% to 20% of patients with ulcerative colitis will ultimately require surgery during their lifetime. The standard surgical procedure for UC is a proctocolectomy (removal of the entire colon and rectum) with ileal pouch-anal anastomosis (IPAA), commonly known as a "J-pouch" procedure. In this surgery, the surgeon creates a reservoir from the end of the small intestine and connects it to the anal canal, allowing the patient to have bowel movements without a permanent ostomy bag.

Surgery may be recommended in the following situations:

• Medical therapy failure: When medications are unable to adequately control symptoms, achieve remission, or maintain remission despite appropriate dose escalation and drug changes.
• Medication intolerance: When side effects from UC medications are severe or unacceptable and no alternative medications are available or tolerated.
• Dysplasia or colorectal cancer: If surveillance colonoscopy detects dysplasia (precancerous cellular changes) or colorectal cancer, colectomy is typically recommended to eliminate the cancer risk.
• Fulminant colitis or toxic megacolon: Severe, life-threatening flares that do not respond to intensive intravenous medical therapy may require emergency colectomy.
• Growth impairment in children: Pediatric patients with UC who experience growth failure despite medical treatment may benefit from surgery.

While surgery is a major decision, many patients report significant improvement in quality of life after a J-pouch procedure. Dr. John works closely with experienced colorectal surgeons in the Dallas-Fort Worth area to coordinate surgical care when it is appropriate, ensuring continuity of care before, during, and after surgery.

Living with Ulcerative Colitis

Ulcerative colitis is a lifelong condition, but with modern medical management and a proactive approach to care, the majority of patients can achieve sustained remission and lead full, productive lives. Understanding the disease and developing effective strategies for managing it are essential to long-term well-being.

Flares and Remission

The natural course of ulcerative colitis alternates between flares (periods of active symptoms) and remission (periods of minimal or no symptoms). The most important factor in preventing flares is consistent adherence to prescribed maintenance medication, even when you feel well. Stopping or reducing medication during remission is one of the most common causes of disease relapse. Working with your gastroenterologist to identify and avoid personal triggers — such as NSAIDs, specific stressors, or missed doses — can also help reduce flare frequency.

Diet and Nutrition

There is no single diet that causes or cures ulcerative colitis. However, dietary modifications can play a supportive role in managing symptoms, particularly during flares. During active disease, many patients find that a low-residue diet (reducing high-fiber foods, raw fruits and vegetables, seeds, and nuts) helps minimize diarrhea and cramping. During remission, a well-balanced diet rich in fruits, vegetables, lean proteins, and whole grains is generally recommended. Some patients benefit from working with a registered dietitian experienced in IBD to identify specific food triggers and ensure adequate nutrition, particularly if weight loss or nutritional deficiencies are present.

Mental Health

Living with a chronic illness like ulcerative colitis can take a significant emotional toll. Studies have shown that rates of anxiety and depression are higher in IBD patients than in the general population, and psychological distress can, in turn, worsen disease activity and quality of life. Dr. John encourages patients to address mental health as part of their overall UC management plan. Cognitive behavioral therapy, mindfulness-based stress reduction, and, when appropriate, medication for anxiety or depression have all been shown to benefit IBD patients. Patient support groups through organizations like the Crohn's & Colitis Foundation can also provide valuable peer connection and resources.

Cancer Surveillance

Patients with ulcerative colitis that extends beyond the rectum have an increased risk of developing colorectal cancer over time. The risk becomes clinically significant approximately 8 to 10 years after the onset of UC symptoms and increases with longer disease duration and greater extent of colonic involvement. The ACG recommends that patients with left-sided colitis or pancolitis begin surveillance colonoscopy every 1 to 3 years starting 8 years after symptom onset. Surveillance colonoscopies in UC patients should ideally use chromoendoscopy (applying dye to the colon surface to enhance detection of subtle dysplasia) or high-definition white-light endoscopy with targeted biopsies. Patients with concurrent primary sclerosing cholangitis (PSC) have an even higher risk and should begin annual surveillance colonoscopies at the time of their PSC diagnosis.

Pregnancy and Family Planning

Women with ulcerative colitis can have healthy pregnancies and deliveries. The most important factor for a successful pregnancy outcome is achieving remission before conception and maintaining disease control throughout pregnancy. Active inflammation during pregnancy is associated with a higher risk of preterm birth, low birth weight, and other complications. Most UC medications, including aminosalicylates and many biologics, are considered safe to continue during pregnancy. Dr. John works closely with patients and their obstetricians to develop a coordinated care plan that optimizes both maternal and fetal health. Family planning discussions should take place well before conception to ensure the safest possible approach.

Frequently Asked Questions